Jose Pascual, MD
Pulmonary Disease · Hudson, FLNPI 1801896956
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,836 of the $22,422 with a category attached, or 66.2%. 46 manufacturers reported payments, led by Boehringer Ingelheim at 34.3% of the total. Reporting peaked in 2019 at $6,813 and has fallen 62.9% since, to $2,527 in 2025.
Across 748 payments — averaging $29.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$8K
- AstraZeneca$2K
- GSK$2K
- Actelion Pharmaceuticals US, Inc.$2K
- Intuitive Surgical$1K
- Grifols USA, LLC$674
- plus $6K from 40 others
Across 15 payments — averaging $5323.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Actelion Pharmaceuticals, Ltd$48K
- Actelion Pharmaceuticals US, Inc.$19K
- Janssen Research & Development, LLC$13K
What the payments were for
- Consulting fees$2,80813%
- Speaking & faculty fees$3,69016%
- Travel & lodging$6793%
- Food & beverage$14,83666%
- Education$4092%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$2,808
- Da Vinci Surgical System$1,050
- ORENITRAM$125
- TRELEGY ELLIPTA$111
- UPTRAVI$108
- Adempas$100
How this compares
$22,422 in reported general payments places this provider in the 85th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 74 | $920,751 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 966 | $901,962 |
| UptraviSelexipag | 24 | $548,267 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 53 | $469,319 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 410 | $329,661 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $184,211 |
| AdempasRiociguat | 11 | $154,964 |
| OfevNintedanib Esylate | 11 | $144,943 |
| Spiriva RespimatTiotropium Bromide | 161 | $126,940 |
| TezspireTezepelumab-Ekko | 21 | $90,437 |
| XolairOmalizumab | 16 | $88,637 |
| Fasenra PenBenralizumab | 14 | $79,383 |
| SymbicortBudesonide/Formoterol Fumarate | 169 | $61,929 |
| Breo ElliptaFluticasone/Vilanterol | 103 | $60,454 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 56 | $44,905 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $1,787 | $1,469,01898 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $2,211 | $1,020,8031,170 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Bevespi Aerosphere, Airsupra | $2,234 | $499,952641 claims |
| Grifols USA, LLCProlastin C | $674 | $469,31953 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $7,680 | $332,900244 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $654 | $184,21113 claims |
| BayerAdempas | $471 | $154,96411 claims |
| MerckDulera | $232 | $5,93912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Hudson
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.